Treatment of Melasma Using Q-switched Nd: YAG Laser and Fractional CO2 Laser Separately and in Combination
Launched by KASR EL AINI HOSPITAL · Feb 19, 2019
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • melasma patients above 18 years
- Exclusion Criteria:
- • Pregnancy.
- • Usage of chemical peeling 1 month prior to the study.
- • Isotretinoin intake 6 months prior to the study.
- • Any laser procedure related to melasma lesions 1 month prior to the study.
- • Active herpetic lesions.
- • Any concurrent active skin disease within the treated area.
- • Photosensitive skin conditions such as systemic lupus erythematous.
- • History of delayed wound healing.
- • Keloid formation.
- • Bleeding diathesis.
- • Medical conditions such as diabetes mellitus \& autoimmune diseases.
About Kasr El Aini Hospital
Kasr El Aini Hospital, a prestigious medical institution affiliated with Cairo University, is dedicated to advancing healthcare through innovative clinical research. With a commitment to excellence, the hospital serves as a leading sponsor of clinical trials, leveraging its state-of-the-art facilities and a multidisciplinary team of healthcare professionals. The institution focuses on a diverse range of therapeutic areas, aiming to improve patient outcomes and contribute to the global medical community. By fostering collaboration and adhering to the highest ethical standards, Kasr El Aini Hospital plays a pivotal role in the development of new treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, El Manial, Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials